Proactive Investors - Run By Investors For Investors

CytoDyn to begin preclinical studies with leronlimab for 8 different cancers

CytoDyn Inc (OTCQB:CYDY) CEO Dr. Nader Pourhassan and Chief Medical Officer Dr. Richard Pestell tell Proactive Investors its new lab in Philadelphia led by Dr. Pestell will conduct eight pre-clinical studies on melanoma, pancreatic cancer, breast cancer, prostate cancer, colon cancer, lung cancer, liver cancer, and stomach cancer.

Dr. Pestell says these indications were chosen, as they tend to spread fast, and are particularly deadly cancers.

View full CYDY profile View Profile

CytoDyn Timeline

Copyright ©, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use